1Baselga J.The EGFR as a target for anticancer therapy-focus on cetuximab.Eur J Cancer,2001,37(Suppl4):S16-22.
2Huang SM,Bock JM,Harari RM.Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinomas of the head and neck.Cancer Res,1999,59(8):1935-1940.
3Ciardiello F,Bianco R,Damiano V,et al.Antiangiogenic and an titumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.Clin Cancer Res,2000,6(9):3739-3747.
同被引文献15
1NGUTEN KS, NEAL JW. First-line treatment of EGFR-mutant non- small- cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors[J]. Biologics, 2012, 9 (6) : 337-344.
2PATIL N, ABBA M, ALLGAYER H. Cetuximab and biomarkers in non- small- cell lung carcinoma[J]. Biologics: Targets and Therapy, 2012, 6(6): 221-231.
3MENDELSOHN J, BASELGA J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. J Clin Oncol, 2003, 21(14): 2787-2799.
4ETTINGER DS, AKERLEY W. BEPLER G, et al. NCCN clinical practice guidelines in oncology: non- small cell lung cancer[EB/OL]. (2008-09-20)[2013-06-13]. http://www.NCCN. org.
5JALAL S, WATERHOUSE D, EDELMAN MJ, et al. Pemetrexed plus cetuximab in patients with recurrent non small cell lung cancer (NSCLC): A phase I /II study from the hoosier oncology group[J]. Thoracic Oncol, 2009, 4(11 ) : 1420-1424.
6BUTYS CA, BODKIN D, MIDDLEMAN EL, et al. Randomized phase 1I study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer [J]. J Clin Oncol, 2007, 25(36) : 5777-5784.
7ROSELL R, ROBINET G, SZCZESNA A, et al. Randomized phase lI study of cetuximab plus cisplatin/vinorelbine compared withcisplatin/vinorelbine alone as first- line therapy in EGFR- expressing advanced non-small-cell lung cancer[J]. Ann Oncol, 2008, 19(2): 362-369.
8PIRKER R, PEREIRA JR, SZCZESNA A, etal. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase m tialiJ]. Lancet, 2009, 373(9674): 1525-1531.
9LYNCH TJ, PATEL T, DREISBACH L, et al. Cetuximab and first- line taxane/carboplatin chemotherapy in advanced non- small- cell lung cancer: results of the randomized multicenter phase III trial BMS099[J]. J Clin Oncol, 2010, 28(6): 911-917.
10GOVINDAN R, BOGART J, STINCHCOMBE T, et al.Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non- small- cell lung cancer: Cancer andLeukemia Group B trial 30407[J]. J Clin Oncol, 2011, 29(23) : 3120-3125.
